Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Phathom Q3 Revenue Rises 71% to $84.7 Million

None

Phathom Pharmaceuticals (PHAT) reported third-quarter 2026 net revenue of $84.7 million, up 71% from $49.5 million a year earlier and 14% from the second quarter. The company reported a GAAP net loss of $13.9 million, compared with a $30.0 million loss in the prior-year quarter.

VOQUEZNA prescriptions filled exceeded 2 million through October 16, 2026. Phathom reaffirmed its full-year 2026 guidance for net revenue of $310 million to $325 million.

  • Third-quarter product revenue, net: $84.722 million.
  • GAAP net loss per basic and diluted share: $0.16.
  • Approximately 380,000 VOQUEZNA prescriptions were filled during the quarter, including about 248,000 covered prescriptions.
  • Cash and cash equivalents were $184.6 million as of September 30, 2026.
  • Operating cash flow was positive for the second consecutive quarter.

$PHAT Hedge Fund Activity

We have seen 82 institutional investors add shares of $PHAT stock to their portfolio, and 74 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles